SOURCE: Global Media Networks, Inc.

March 03, 2008 08:30 ET

Global Media Networks, Inc. Announces Further Details on Takeover by Biocure Med Inc. and Operational Plan

PRAEKASA MUENG, THAILAND--(Marketwire - March 3, 2008) - Global Media Networks, Inc. (PINKSHEETS: GLMN) today announced further details regarding the takeover by Biocure Med Inc. and its new Operational Plan.

Biocure Med's Chief Executive Officer Mr. Leonard Rosenberg M.D. issued the following statement: "Our decision to execute the takeover of Global Media Networks was mainly driven by the small number of Global Media's outstanding shares, which will facilitate our process to become fully reporting. Biocure Med intends to file a form 10 SB in short order, which will include Biocure Med's audited financial statements for the past 2 years. Our Management team and partners have been very active in preparing for our formal entry into the North American public market. Biocure Med has completed a $10,000,000 private placement for the purpose of building its new Canadian R&D and Production Facility to be operational by fall 2008. Our main goal was to take advantage of the several incentives in the Canadian tax credit program for the research and development expenditures of Biotechnology Companies."

Senior Vice President, R & D and Project Management Alan Rossy, Ph.D. indicated the following: "Following our recent breakthrough discoveries in the treatment of diabetes, our management team has decided to file all requisite documentation to obtain a NPN (Natural Product Number) from the Canadian Health Care Department. Obtaining this certification will allow us to go to market rapidly and generate revenues from the commercialization of the 'DiaCure™ Therapy.' Our work team has completed an agreement with an existing Canadian production facility and following minor renovations and addition of key equipment and technology, Biocure will be able to commence production during fall 2008."

About Biocure Med Inc.

Biocure Med Inc. (Biocure) is a biotechnology company specialized in the research, discovery, development and commercialization of medication that potentially cure or stabilize diseases and respond to patients' medical needs. Biocure's proprietary medication product lines under development are centered on the treatment of Diabetes and Alzheimer's disease. Biocure's goal and vision is to become a major player and the world's leading developer of breakthrough therapeutic products in the biotechnology industry. During the last 12 years, Biocure has been built into a fully integrated, commercial-stage biopharmaceutical company that invents, develops and markets safe and effective drugs to treat patients with chronic, debilitating and life-threatening diseases, primarily Diabetes and Alzheimer's. Biocure's new public venue will allow it to expand and rapidly distribute its new breakthrough products in North America and Europe.

For more information please visit the new in-progress Corporate Website at www.biocuremed.com.

To speak with Investor Relations, shareholders may call: David L. Basehart at 613-482-1778 or via email at ir@biocuremed.com.

Forward-Looking Statements

Please be advised that statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company's stock price, increased competition, customer acceptance of new products and services offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating results. Please also be advised that the company's stock is not currently registered with the Securities and Exchange Commission.

Contact Information